Rapport Therapeutics, Inc. (RAPP) Stock Price & Analysis

Rapport Therapeutics, Inc. (RAPP) closed at USD 26.53 on Thursday, October 22, 2026, up 5.87% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 25.06; the Oct 22, 2026 session ranged USD 25.81–27.89 on volume of 1,458,606 shares. Market capitalization is $1.27B, with a 52-week range of USD 23.75–52.93 (NGM). Source: Nexqual, retrieved October 23, 2026 at 08:35 UTC.

Also available as compact Markdown for AI agents: nexqual.com/RAPP.md

Key facts (RAPP)

• Analysts: Buy (mean 1.94 on a 1–5 scale) (16 analysts), mean target USD 69.4 (range 50–91).
• Total return with dividends: 1Y +1.3% vs S&P 500 +14.9%; 5Y +27.6% vs S&P 500 +80.3%.
• Next earnings: 2026-11-05, EPS estimate USD -1.22, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RAPP)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (RAPP)

P/B 3.0x · FCF yield -7.63% · Earnings yield -10.78%

Analysts (RAPP)

Consensus Buy (mean 1.94 on a 1–5 scale), 16 analysts; mean target USD 69.4 (low 50, high 91).

Rating changes, last 120 days:

Total return (dividends reinvested) (RAPP)

RAPP suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 10, 2026.

Companies that name RAPP in their SEC reports

RAPP company outlook (results filed Aug 5, 2026)

• “Tenacia expects patient recruitment in China to begin in 4Q 2026. • Open-label Safety Trial Initiated.”
• “The majority of patients from the RAP-219 Phase 2 trial in FOS have now enrolled in the open-label long term safety trial, with initial data expected in the fourth quarter of 2026. ·”
• “The Phase 2 trial continues to progress, with topline results expected in October 2026.”
• “IND-enabling activities for RAP-219's long-acting injectable formulation continue, with initial Phase 1 pharmacokinetic data expected in 2027. ·”

Quoted word-for-word from the SEC 8-K results press release.

RAPP analyst estimates and revisions

RAPP options: expected move

Options price a move of about ±17.7% (±$4.85) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±4.8% on average.

30-day implied volatility 72.8% vs 83.3% realized over the last 30 trading days. Put/call ratio (volume) 79.39. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 08:35 UTC)

Technical Analysis (RAPP)

Nexqual's technical model rates RAPP "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 08:35 UTC.

Analyst Ratings (RAPP)

Wall Street analysts rate RAPP "Buy" based on 16 analysts, with a mean price target of USD 69.4 (range USD 50–91), per Nexqual as of October 23, 2026 at 08:35 UTC.

Earnings (RAPP)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 08:35 UTC.

Financials & Fundamentals (RAPP)

Source: Nexqual, October 23, 2026 at 08:35 UTC.

Financial Health Score (RAPP)

Nexqual rates Rapport Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 08:35 UTC.

Ownership (RAPP)

Source: Nexqual, October 23, 2026 at 08:35 UTC.

Leadership (RAPP)

Rapport Therapeutics, Inc. is led by Abraham N. Ceesay, CEO, President, Treasurer & Director, per Nexqual as of October 23, 2026 at 08:35 UTC.

Major Backers & Investors (RAPP)

Notable institutional backers of Rapport Therapeutics, Inc. include FMR, LLC, Trv Gp V, LLC , Fidelity, according to Nexqual as of October 23, 2026 at 08:35 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 08:35 UTC.

From Rapport Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)

Key Strengths & Strategy (as disclosed to the SEC)

• Epilepsy is estimated to affect 50 million people worldwide, including approximately 3.0 million adults in the United States ("United States" or "U.S.").
• Our foundational science has elucidated the complexities of neuronal receptor biology and enables us to map and target certain neuronal receptor complexes.
• We currently have exclusive global rights to use our technology platform and to commercialize our product candidates.
• We have designed our platform to prosecute a wide range of validated therapeutic targets.

Partnerships

• In August 2022, we entered into a license agreement with Janssen (the "Janssen License") for the research, development and commercialization of certain TARP8 products, including RAP-219, as well as nAChR projects created by Dr.
• In November 2023, we established a collaboration with NeuroPace to leverage the RNS system's data to track responses of patients receiving RAP-219 in our Phase 2a proof-of-concept trial.

Legal & Regulatory Risks (Item 1A, quoted)

• We may also submit marketing applications in other countries.
• We may seek Breakthrough Therapy Designation for any product candidate that we develop.
• Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
• We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 08:35 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt